Claims for Patent: 10,485,793

Summary for Patent: 10,485,793

Title:	Regimen for suppressing organ rejection
Abstract:	The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower C.sub.max than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
Inventor(s):	Polvino; William J. (Edison, NJ)
Assignee:	VELOXIS PHARMACEUTICALS A/S (Kobenhavn, DK)
Application Number:	15/682,275
Patent Claims:	1. A method of suppressing organ rejection in a de novo kidney transplant recipient, the method comprising initiating oral treatment with a once-daily extended release tacrolimus formulation at an initial dose of from about 0.15 to about 0.20 mg/kg/day following transplantation, wherein (i) the once-daily extended release tacrolimus formulation provides a fluctuation of less than 80% and a swing less than 120%; and (ii) the once-daily extended release tacrolimus formulation releases the tacrolimus substantially in the colon and/or the lower ileum. 2. The method of claim 1, wherein dosing is initiated within 48 hours following transplantation. 3. The method of claim 1, wherein the extended release formulation releases at least 50% of the tacrolimus in the colon and/or the lower ileum. 4. The method of claim 1, wherein the extended release formulation releases at least 50% of the tacrolimus in one or more of the colon ascendens, colon transversum and colon decendens. 5. The method of claim 1, wherein the formulation comprises (a) granules of tacrolimus and a hydrophilic vehicle in the pores of and/or on an inert porous solid carrier, and (b) a release modifying agent. 6. The method of claim 1, wherein the formulation is prepared by compressing into a tablet a mixture of (a) granules of tacrolimus and a hydrophilic vehicle in the pores of and/or on an inert porous solid carrier, and (b) a release modifying agent. 7. The method of claim 6, wherein the granules are prepared by spraying a mixture of tacrolimus in a melted hydrophilic vehicle onto the inert porous solid carrier. 8. The method of claim 1, wherein the once-daily extended release tacrolimus formulation releases at most 63.5% of the tacrolimus in the formulation at the 12 hours time point, when tested according to USP II dissolution test (paddle) method in 900 ml of an aqueous medium at pH 4.5 and comprising 0.005% hydroxypropylcellulose and 0.5% of the surfactant sodium lauryl sulfate, at 37.degree. C..+-.0.5.degree. C. and a paddle speed of 100 rpm. 9. The method of claim 1, further comprising adjusting the dose of the extended release tacrolimus formulation so that the whole blood pre-dose concentration of tacrolimus is maintained in the range of from about 8.8 to about 9.3 ng/mL from day 2 to week 3 of tacrolimus treatment, and from about 6.5 to about 8.8 ng/mL for month 1 to 12. 10. The method of claim 1, wherein the recipient is African-American. 11. A method of suppressing organ rejection in a de novo kidney transplant recipient, the method comprising (a) initiating oral treatment with a once-daily extended release tacrolimus formulation at an initial dose of from about 0.15 to about 0.20 mg/kg/day following transplantation, wherein (i) the once-daily extended release tacrolimus formulation provides a fluctuation of less than 80% and a swing less than 120%; and (ii) the once-daily extended release tacrolimus formulation releases the tacrolimus substantially in the colon and/or the lower ileum; and (b) concomitantly treating the recipient with an IL-2 receptor antagonist and mycophenolate mofetil. 12. The method of claim 11, wherein the recipient is African-American. 13. The method of claim 12, wherein dosing is initiated within 48 hours following transplantation. 14. The method of claim 12, wherein dosing is initiated within 24 hours following transplantation. 15. The method of claim 12, wherein the IL-2 receptor antagonist is basiliximab. 16. The method of claim 12, wherein 1 g of mycophenolate mofetil is administered twice daily. 17. The method of claim 12, further comprising concomitantly treating the recipient with one or more corticosteroids. 18. The method of claim 11, wherein the extended release formulation releases at least 50% of the tacrolimus in the colon and/or the lower ileum.

Details for Patent 10,485,793

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2033-06-27
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003		2033-06-27